Literature DB >> 30802411

Ibrutinib-associated Serositis in Mantle Cell Lymphoma.

Brett A Styskel1, Juan Lopez-Mattei2, Carlos A Jimenez3, John Stewart4, Fredrick B Hagemeister5, Saadia A Faiz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30802411      PMCID： PMC6580678          DOI： 10.1164/rccm.201809-1738IM

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  5 in total

Review 1.  Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.

Authors:  Bronwyn C Thorp; Xavier Badoux
Journal:  Leuk Lymphoma       Date:  2017-06-20

Review 2.  A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.

Authors:  Chung-Shien Lee; Mohammad A Rattu; Sara S Kim
Journal:  J Oncol Pharm Pract       Date:  2014-11-25       Impact factor: 1.809

3.  Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Authors:  Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

4.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

Review 5.  Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Authors:  Kevin Kelly; Ronan Swords; Devalingam Mahalingam; Swaminathan Padmanabhan; Francis J Giles
Journal:  Target Oncol       Date:  2009-04-21       Impact factor: 4.493
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.